Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-463
Closed -$31K 658
2022
Q3
$31K Sell
463
-20
-4% -$1.48K ﹤0.01% 367
2022
Q2
$37K Buy
483
+380
+369% +$28.9K ﹤0.01% 345
2022
Q1
$8K Hold
103
﹤0.01% 559
2021
Q4
$8K Hold
103
﹤0.01% 571
2021
Q3
$7K Hold
103
﹤0.01% 569
2021
Q2
$9K Hold
103
﹤0.01% 509
2021
Q1
$8K Hold
103
﹤0.01% 529
2020
Q4
$9K Hold
103
﹤0.01% 499
2020
Q3
$9K Sell
103
-60
-37% -$5.79K ﹤0.01% 458
2020
Q2
$17K Buy
163
+31
+23% +$2.99K ﹤0.01% 370
2020
Q1
$10K Buy
+132
New +$9.97K ﹤0.01% 422
2018
Q4
Sell
-335
Closed -$23K 859
2018
Q3
$23K Buy
+335
New +$23K ﹤0.01% 378
2018
Q2
Sell
-100
Closed -$8K 872
2018
Q1
$8K Buy
+100
New +$9.02K ﹤0.01% 529
2016
Q2
Sell
-200
Closed -$14K 1002
2016
Q1
$14K Buy
+200
New +$14.9K ﹤0.01% 466

Other funds holding INCY

Howe & Rusling's INCY Position: Q4 2022 in Review

Howe & Rusling sold out of Incyte (INCY) in Q4 2022, closing a stake of 463 shares — an estimated $31K sold.

Howe & Rusling first reported a position in INCY in Q1 2016 and held it in 14 quarters. The position peaked at $37K in Q2 2022. 558 funds tracked by Wall St. Rank hold INCY as of Q4 2022.

  • Howe & Rusling reported no remaining Incyte position as of Q4 2022 after selling out during the quarter.
  • Howe & Rusling sold 463 Incyte shares in Q4 2022, an estimated $31K.
  • Howe & Rusling first reported a position in Incyte in Q1 2016 and held it in 14 quarters.
  • Howe & Rusling's Incyte position peaked at $37K in Q2 2022.
  • 558 funds tracked by Wall St. Rank held Incyte as of Q4 2022.

Based on Howe & Rusling's 13F filing for Q4 2022, filed 15 Feb 2023.